Sinopharm Group Return On Asset vs. Cash Per Share
| X2S Stock | EUR 2.45 0.03 1.24% |
For Sinopharm Group profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sinopharm Group to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sinopharm Group Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sinopharm Group's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sinopharm Group Co over time as well as its relative position and ranking within its peers.
Sinopharm |
Sinopharm Group Cash Per Share vs. Return On Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Sinopharm Group's current stock value. Our valuation model uses many indicators to compare Sinopharm Group value to that of its competitors to determine the firm's financial worth. Sinopharm Group Co is rated first in return on asset category among its peers. It is rated first in cash per share category among its peers fabricating about 302.47 of Cash Per Share per Return On Asset. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sinopharm Group's earnings, one of the primary drivers of an investment's value.Sinopharm Cash Per Share vs. Return On Asset
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Sinopharm Group |
| = | 0.0364 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Sinopharm Group |
| = | 11.01 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Sinopharm Cash Per Share Comparison
Sinopharm Group is currently under evaluation in cash per share category among its peers.
Sinopharm Group Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Sinopharm Group, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sinopharm Group will eventually generate negative long term returns. The profitability progress is the general direction of Sinopharm Group's change in net profit over the period of time. It can combine multiple indicators of Sinopharm Group, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the Peoples Republic of China. The company was founded in 2003 and is headquartered in Shanghai, the Peoples Republic of China. SINOPHARM GRP operates under Medical Distribution classification in Germany and is traded on Frankfurt Stock Exchange. It employs 108370 people.
Sinopharm Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Sinopharm Group. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sinopharm Group position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sinopharm Group's important profitability drivers and their relationship over time.
Use Sinopharm Group in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sinopharm Group position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sinopharm Group will appreciate offsetting losses from the drop in the long position's value.Sinopharm Group Pair Trading
Sinopharm Group Co Pair Trading Analysis
The ability to find closely correlated positions to Sinopharm Group could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sinopharm Group when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sinopharm Group - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sinopharm Group Co to buy it.
The correlation of Sinopharm Group is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sinopharm Group moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sinopharm Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sinopharm Group can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Sinopharm Group position
In addition to having Sinopharm Group in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Latest Gainers Thematic Idea Now
Latest Gainers
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Gainers theme has 225 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Gainers Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Sinopharm Stock
To fully project Sinopharm Group's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sinopharm Group at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sinopharm Group's income statement, its balance sheet, and the statement of cash flows.